Artal Group’s Bio-Techne TECH Stock Holding History

Artal Group’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-240,000	Closed	-$19.1M	–	163
2020 Q4	$19.1M	Hold	240,000	–	–	0.41%	60
2020 Q3	$14.9M	Sell	240,000 -20,000	-8%	-$1.3M	0.36%	58
2020 Q2	$17.2M	Buy	+260,000	New	+$15.6M	0.48%	48

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return

Artal Group's TECH Position: Q1 2021 in Review

Artal Group sold out of Bio-Techne (TECH) in Q1 2021, closing a stake of 240,000 shares — an estimated $19.1M sold.

Artal Group first reported a position in TECH in Q2 2020 and held it in 3 quarters. The position peaked at $19.1M in Q4 2020. 471 funds tracked by Wall St. Rank hold TECH as of Q1 2021.

Artal Group reported no remaining Bio-Techne position as of Q1 2021 after selling out during the quarter.
Artal Group sold 240,000 Bio-Techne shares in Q1 2021, an estimated $19.1M.
Artal Group first reported a position in Bio-Techne in Q2 2020 and held it in 3 quarters.
Artal Group's Bio-Techne position peaked at $19.1M in Q4 2020.
471 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2021.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.